GlassScriptPhysician profile
Emeka Augustus Uwakwe
NPI 1427059096
$2,742.15
in general payments reported to CMS, 2019-2025
24 companies · $301 in 2025
The $301 reported for 2025 was more than what 84% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $222 · 2021: $766 · 2022: $334 · 2023: $277 · 2024: $406 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,051.19 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $291.09 | 2019-2025 | Farxiga, Lokelma, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.76 | 2020-2025 | Jardiance, Combivent Respimat, Spiriva Respimat |
| Alexion Pharmaceuticals, INC. | $163.34 | 2021-2024 | Ultomiris |
| Pfizer INC. | $139.11 | 2019-2024 | |
| Abbott Laboratories | $118.03 | 2019-2025 | Freestyle Libre, Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $105.80 | 2019-2025 | Eliquis |
| Melinta Therapeutics, LLC | $87.11 | 2024-2025 | Orbactiv |
| Medtronic USA, INC. | $72.64 | 2020 | |
| Amgen INC. | $67.10 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $56.90 | 2020-2025 | General - Therapies |
| Genzyme Corporation | $53.23 | 2024 | |
| Smith+Nephew, INC. | $50.89 | 2025 | Collagenase Santyl |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.89 | 2019-2020 | |
| Gilead Sciences, INC. | $41.04 | 2023-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $40.32 | 2019-2020 | |
| Celgene Corporation | $21.65 | 2019 | |
| Solventum Corporation | $20.66 | 2024 | V.A.C. Veraflo Cleanse Choice |
| Lilly USA, LLC | $19.34 | 2019 | |
| La Jolla Pharmaceutical Company | $16.84 | 2023 | Xerava |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.87 | 2021 | |
| Tesaro, INC. | $15.00 | 2019 | |
| Kyowa Kirin, INC. | $14.09 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emeka Uwakwe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.